Basket cover image
17 handpicked stocks

Telecom's Patent Powerhouses

A $175 million verdict against Verizon for patent infringement highlights the increasing power of intellectual property holders in the telecom industry. This creates an investment opportunity in companies that own and license critical technology patents, as they are now better positioned to enforce their rights and secure lucrative licensing agreements.

stock
stock
stock
stock
stock
stock
stock
stock
stock
stock

+7

Author avatar

Han Tan | Market Analyst

Updated 3 days ago | Published at जुलाई 24

Top Picks from This Group

Here are a few of the assets in this group. Create an account to unlock the full list.

IDCC

InterDigital, Inc.

IDCC

Current price

$260.33

Leading wireless technology innovator with extensive patent portfolio in mobile communications.

NTIP

Network-1 Technologies Inc

NTIP

Current price

$1.42

Patent licensing company focused on wireless and networking technologies.

ERIC

Telefonaktiebolaget LM Ericsson

ERIC

Current price

$7.69

Global telecommunications equipment manufacturer with substantial R&D-driven patent portfolio.

About This Group of Stocks

1

Our Expert Thinking

A recent $175 million patent verdict against Verizon signals a new era where intellectual property holders have stronger legal precedent for enforcement. This creates opportunities for companies that own valuable telecom patents to secure lucrative licensing deals or favorable settlements.

2

What You Need to Know

This group includes companies ranging from pure-play patent licensing firms to major equipment manufacturers with substantial R&D portfolios. Their business models focus on generating high-margin revenue through licensing agreements and patent enforcement in the telecommunications sector.

3

Why These Stocks

These companies were handpicked for their strong, defensible intellectual property in wireless communication technologies. With increasing legal precedent for significant patent payouts, they're positioned to potentially capitalize on stricter enforcement trends.

12 Month Growth Potential

Use the growth calculator to see how much investing in these assets could return over one year.

If you invested across these assets:

in 12 months it could be worth:

$1,000.00

+25.00%

Group Performance Snapshot

25%

Average 12 Month Profit

On average, analysts expect assets in this group to grow 25% over the next year.

10 of 17

Stocks Rated Buy by Analysts

10 of 17 assets in this group are rated Buy by professional analysts.

8.9% vs 4%

Group Growth vs Bank interest

This group averaged a 8.9% return last month, beating the typical 4% bank rate.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Why You'll Want to Watch These Stocks

⚖️

Legal Precedent Shift

The $175 million verdict against Verizon signals courts are taking patent infringement more seriously. This strengthens the hand of companies with valuable intellectual property portfolios.

💰

High-Margin Revenue Potential

Patent licensing generates exceptional profit margins with minimal ongoing costs. Companies with strong IP portfolios could see significant revenue boosts from enforcement actions.

🔒

Defensible Market Position

Owning critical telecom patents creates competitive moats that are difficult to replicate. These companies control foundational technologies essential for modern wireless communication.

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

The New Cost of Compliance: Investing in HR Tech

The New Cost of Compliance: Investing in HR Tech

Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.

View stocks
GLP-1s Target Liver Disease

GLP-1s Target Liver Disease

The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.

View stocks
Pharma's Digital Prescription

Pharma's Digital Prescription

Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.

View stocks
View All Stock Groups

Frequently Asked Questions

Everything you need to know about the product and billing.